Withdrawing Vioxx: important lessons in communication strategy from Merck & Co. Inc.

Abstract

Purpose

Reviews the latest management developments across the globe and pinpoints practical implications from cutting‐edge research and case studies.

Design/methodology/approach

This briefing is prepared by an independent writer who adds their own impartial comments and places the articles in context.

Findings

Merck & Co. Inc. is a global research‐driven pharmaceutical company that develops, manufactures and markets a broad range of human health products. One such product is Vioxx, developed in a Merck research facility in 1994 and approved in 1999 by the United States Food and Drug Administration (FDA) for the treatment of pain, inflammation, and stiffness caused by arthritis. The drug was also later approved for use in the treatment of rheumatoid arthritis in both children and adults.

Practical implications

Provides strategic insights and practical thinking that have influenced some of the world's leading organizations.

Originality/value

The briefing saves busy executives and researchers hours of reading time by selecting only the very best, most pertinent information and presenting it in a condensed and easy‐to‐digest format.

Citation

(2007), "Withdrawing Vioxx: important lessons in communication strategy from Merck & Co. Inc.", Strategic Direction, Vol. 23 No. 1, pp. 9-11. https://doi.org/10.1108/02580540710716527